Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$350,816.00
Dec 1, 2021
For-profit organization
Determination of oral efficacy GPS-491 in an animal model of SARS-CoV-2
987152
ViroCarb has developed, in collaboration with leading academics in molecular genetics, functional proteomics, and medicinal chemistry, a paradigm-shifting drug platform to stop the replication of multiple viruses, by targeting a cellular function essential for their propagation in cells (RNA processing). Our preclinical drug candidate GPS-491 is highly effective in inhibiting the replication of multiple viruses including SARS-CoV2 and other members of the coronavirus family in human cells. Our goal is to conduct in vivo efficacy studies of our drug candidate in a COVID-19 model of infection in ACE2 transgenic mice, as well as to conduct target validation studies to support the clinical development of a new therapy for COVID-19.